⌕
Krystal Biotech · KRYS · Nasdaq
Tenet 66 · Solid
Compare
$298.55+0.22%At closeTenet 66 · Solid
$298.55+0.65 (+0.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Krystal Biotech (KRYS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~177.0%/yr (FY23→FY25), net margin 52.6%, and free cash flow (~$188.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+34.9%) and Capex step-up ($12.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲33.9%
389.1
FY21→FY25CAGR —
Net income ($M)▲129.7%
204.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▲58.5%
188.9
capex stepped upCAGR —
Diluted EPS▲128.0%
6.84
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+34.9%

22.2mn → 30.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$12.0M

▲182% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)389.1Revenue−23.0COGS366.1Gross profit−58.0R&D−146.7SG&A161.3Op income43.5Tax & other204.8Net income

53¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin 52.6% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
470.0389.1290.550.70.00.0▲33.9%—
Cost of revenue
26.923.020.13.10.00.0▲14.9%—
Gross profit
443.1366.1270.547.60.00.0▲35.4%—
Research & development
59.558.053.646.442.527.9▲8.3%+20.1%
Selling, general & admin
156.1146.7113.698.377.740.4▲29.1%+38.1%
Total operating expenses
215.6204.8204.7157.2145.268.3▲0.0%+31.6%
Operating incomefeeds ROC rank
227.5161.365.7−109.6−145.2−68.3▲145.3%—
Other income, net
31.328.229.6122.55.2−1.3——
Pretax income
258.8189.595.412.9−140.0−69.6▲98.7%—
Income tax
33.6−15.46.22.00.00.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
225.2204.889.210.9−140.0−69.6▲129.7%—
Per share
Diluted EPSbuyback-sensitive
7.366.843.000.39−5.49−3.13▲128.0%—
Diluted shares (mn)
30.8429.9529.7427.7525.4922.20▲0.7%+7.8%
Margins
Gross margin91st pct in Healthcare
94.3%94.1%93.1%93.9%——▲1.0pp+0.2pp
Operating margin
48.4%41.5%22.6%−216.2%——▲18.8pp+257.7pp
Net margin99th pct in Healthcare
47.9%52.6%30.7%21.6%——▲21.9pp+31.1pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was 15% vs a 0% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was −8% vs a 0% norm for this window, likely a one-time item; see the filing.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Krystal Biotech's revenue last fiscal year?

Krystal Biotech reported revenue of $389.1M in fiscal 2025, up 33.9% from fiscal 2024.

What was Krystal Biotech's net income?

Krystal Biotech reported net income of $204.8M in fiscal 2025, a net margin of 52.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.